These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30025617)

  • 1. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: SYNERGY II study.
    Alcántara Montero A
    Actas Urol Esp (Engl Ed); 2019; 43(1):51-52. PubMed ID: 30025617
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
    de Greef-van der Sandt I; Newgreen D; Schaddelee M; Dorrepaal C; Martina R; Ridder A; van Maanen R
    Clin Pharmacol Ther; 2016 Apr; 99(4):442-51. PubMed ID: 26422298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
    Soliman MG; El-Abd S; El-Gamal OM; Raheem AA; Abou-Ramadan AR; El-Abd AS
    Urol Int; 2021; 105(11-12):1011-1017. PubMed ID: 34010843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
    Drake MJ; MacDiarmid S; Chapple CR; Esen A; Athanasiou S; Cambronero Santos J; Mitcheson D; Herschorn S; Siddiqui E; Huang M; Stoelzel M
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28419650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony).
    Cruz F
    Eur Urol; 2015 Jun; 67(6):1189-90. PubMed ID: 25944037
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy for an overactive bladder.
    Thiagamoorthy G; Cardozo L; Srikrishna S
    Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
    Alcántara-Montero A
    Actas Urol Esp; 2016 Nov; 40(9):593-594. PubMed ID: 27126125
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination of solifenacin and mirabegron for overactive bladder management.
    Cornu JN
    BJU Int; 2015 Oct; 116(4):498-9. PubMed ID: 26350574
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER
    Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
    MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
    J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
    Mueller ER; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Stoelzel M; Yoon SJ; Al-Shukri S; Rechberger T; Gratzke C
    Neurourol Urodyn; 2019 Feb; 38(2):779-792. PubMed ID: 30644570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.